Publisher Correction: A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage

Marcus J G W Ladds^#^{1

2}, Ingeborg M M van Leeuwen^#¹, Catherine J Drummond^#¹, Su Chu³, Alan R Healy⁴, Gergana Popova¹, Andrés Pastor Fernández¹, Tanzina Mollick^{1

2}, Suhas Darekar^{1

2}, Saikiran K Sedimbi^{1

2}, Marta Nekulova^{1

5}, Marijke C C Sachweh¹, Johanna Campbell⁶, Maureen Higgins⁶, Chloe Tuck¹, Mihaela Popa⁷, Mireia Mayoral Safont⁷, Pascal Gelebart⁷, Zinayida Fandalyuk⁷, Alastair M Thompson⁸, Richard Svensson⁹, Anna-Lena Gustavsson¹⁰, Lars Johansson¹⁰, Katarina Färnegårdh¹¹, Ulrika Yngve¹², Aljona Saleh¹², Martin Haraldsson¹¹, Agathe C A D'Hollander⁴, Marcela Franco¹, Yan Zhao¹³, Maria Håkansson¹⁴, Björn Walse¹⁴, Karin Larsson¹, Emma M Peat¹⁵, Vicent Pelechano², John Lunec¹³, Borivoj Vojtesek⁵, Mar Carmena¹⁵, William C Earnshaw¹⁵, Anna R McCarthy¹, Nicholas J Westwood⁴, Marie Arsenian-Henriksson¹, David P Lane^{1

2}, Ravi Bhatia³, Emmet McCormack^{7

16}, Sonia Laín^{17

18}

Affiliations

¹ Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, SE-171 77, Stockholm, Sweden.
² SciLifeLab, Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, Tomtebodavägen 23, SE-171 21, Stockholm, Sweden.
³ Division of Hematology and Oncology, Comprehensive Cancer Center, 1720 2nd Avenue South, NP2540, Birmingham, AL, 35294-3300, USA.
⁴ School of Chemistry and Biomedical Sciences Research Complex, University of St. Andrews and EaStCHEM, St. Andrews, Fife, Scotland, KY16 9ST, UK.
⁵ RECAMO, Masaryk Memorial Cancer Institute, Zluty Kopec 7, 65653, Brno, Czech Republic.
⁶ Centre for Oncology and Molecular Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, Tayside, DD1 9SY, UK.
⁷ Centre for Cancer Biomarkers, CCBIO, Department of Clinical Science, Hematology Section, University of Bergen, 5021, Bergen, Norway.
⁸ Department of Breast Surgical Oncology, MD Anderson Cancer Center, Holcombe Boulevard, Houston, TX, 77030, USA.
⁹ Department of Pharmacy, Uppsala University Drug Optimization and Pharmaceutical Profiling Platform (UDOPP), Department of Pharmacy, Uppsala University, SE-752 37, Uppsala, Sweden.
¹⁰ Chemical Biology Consortium Sweden, Science for Life Laboratory, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, SE-171 21, Stockholm, Sweden.
¹¹ Drug Discovery and Development Platform, Science for Life Laboratory, Tomtebodavägen 23, SE-171 21, Solna, Sweden.
¹² Department of Medicinal Chemistry, Science for Life Laboratories, Uppsala University, SE-751 23, Uppsala, Sweden.
¹³ Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle, NE1 7RU, UK.
¹⁴ SARomics Biostructures, Medicon Village, SE-223 81, Lund, Sweden.
¹⁵ The Wellcome Trust Centre for Cell Biology, Institute of Cell Biology, University of Edinburgh, Edinburgh, EH9 3JR, UK.
¹⁶ Department of Medicine, Haematology Section, Haukeland University Hospital, Bergen, Norway.
¹⁷ Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, SE-171 77, Stockholm, Sweden. sonia.lain@ki.se.
¹⁸ SciLifeLab, Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, Tomtebodavägen 23, SE-171 21, Stockholm, Sweden. sonia.lain@ki.se.

^# Contributed equally.

PMID: 37596290
PMCID: PMC10439212
DOI: 10.1038/s41467-023-40764-2

Published Erratum

Publisher Correction: A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage

Marcus J G W Ladds et al. Nat Commun. 2023.

. 2023 Aug 18;14(1):5019.

doi: 10.1038/s41467-023-40764-2.

Authors

Affiliations

¹ Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, SE-171 77, Stockholm, Sweden.
² SciLifeLab, Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, Tomtebodavägen 23, SE-171 21, Stockholm, Sweden.
³ Division of Hematology and Oncology, Comprehensive Cancer Center, 1720 2nd Avenue South, NP2540, Birmingham, AL, 35294-3300, USA.
⁴ School of Chemistry and Biomedical Sciences Research Complex, University of St. Andrews and EaStCHEM, St. Andrews, Fife, Scotland, KY16 9ST, UK.
⁵ RECAMO, Masaryk Memorial Cancer Institute, Zluty Kopec 7, 65653, Brno, Czech Republic.
⁶ Centre for Oncology and Molecular Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, Tayside, DD1 9SY, UK.
⁷ Centre for Cancer Biomarkers, CCBIO, Department of Clinical Science, Hematology Section, University of Bergen, 5021, Bergen, Norway.
⁸ Department of Breast Surgical Oncology, MD Anderson Cancer Center, Holcombe Boulevard, Houston, TX, 77030, USA.
⁹ Department of Pharmacy, Uppsala University Drug Optimization and Pharmaceutical Profiling Platform (UDOPP), Department of Pharmacy, Uppsala University, SE-752 37, Uppsala, Sweden.
¹⁰ Chemical Biology Consortium Sweden, Science for Life Laboratory, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, SE-171 21, Stockholm, Sweden.
¹¹ Drug Discovery and Development Platform, Science for Life Laboratory, Tomtebodavägen 23, SE-171 21, Solna, Sweden.
¹² Department of Medicinal Chemistry, Science for Life Laboratories, Uppsala University, SE-751 23, Uppsala, Sweden.
¹³ Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle, NE1 7RU, UK.
¹⁴ SARomics Biostructures, Medicon Village, SE-223 81, Lund, Sweden.
¹⁵ The Wellcome Trust Centre for Cell Biology, Institute of Cell Biology, University of Edinburgh, Edinburgh, EH9 3JR, UK.
¹⁶ Department of Medicine, Haematology Section, Haukeland University Hospital, Bergen, Norway.
¹⁷ Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, SE-171 77, Stockholm, Sweden. sonia.lain@ki.se.
¹⁸ SciLifeLab, Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, Tomtebodavägen 23, SE-171 21, Stockholm, Sweden. sonia.lain@ki.se.

^# Contributed equally.

PMID: 37596290
PMCID: PMC10439212
DOI: 10.1038/s41467-023-40764-2

No abstract available

PubMed Disclaimer

Erratum for

A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage.
Ladds MJGW, van Leeuwen IMM, Drummond CJ, Chu S, Healy AR, Popova G, Pastor Fernández A, Mollick T, Darekar S, Sedimbi SK, Nekulova M, Sachweh MCC, Campbell J, Higgins M, Tuck C, Popa M, Safont MM, Gelebart P, Fandalyuk Z, Thompson AM, Svensson R, Gustavsson AL, Johansson L, Färnegårdh K, Yngve U, Saleh A, Haraldsson M, D'Hollander ACA, Franco M, Zhao Y, Håkansson M, Walse B, Larsson K, Peat EM, Pelechano V, Lunec J, Vojtesek B, Carmena M, Earnshaw WC, McCarthy AR, Westwood NJ, Arsenian-Henriksson M, Lane DP, Bhatia R, McCormack E, Laín S. Ladds MJGW, et al. Nat Commun. 2018 Mar 16;9(1):1107. doi: 10.1038/s41467-018-03441-3. Nat Commun. 2018. PMID: 29549331 Free PMC article.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- PubMed Central
Research Materials
- NCI CPTC Antibody Characterization Program

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Publisher Correction: A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage

Affiliations

Publisher Correction: A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage

Authors

Affiliations

Erratum for

Publication types

LinkOut - more resources

Full Text Sources

Research Materials